GSK3B

Across TCGA pan-cancer cohorts, GSK3B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GSK3B data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GSK3B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated GSK3B expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, BLCA, and LIHC are the cancer types where GSK3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.628	.023	20	view →
BLCA	OS	Median	All	0.149	0.687	.005	18	view →
LIHC	OS	Median	All	0.047	0.783	<.001	12	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	6	view →
STAD	OS	Median	IV	0.111	0.433	.002	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.683	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GSK3B–UCEC (DFS)

Open the UCEC breakdown →